Endologix LLC, a privately held, global medical device company dedicated to providing disruptive therapies for the interventional treatment of vascular disease, is pleased to announce that Lucas Buchanan has been appointed to the Endologix Board of Directors.

Lucas Buchanan is currently the Chief Financial Officer and Chief Operating Officer at Silk Road Medical, Inc. He is widely recognized for his contributions to Silk Road Medical as the company introduced a new therapy for the treatment of carotid artery stenosis and changed the paradigm for patients with cerebrovascular disease. Mr. Buchanan played a pivotal role in financing the company and scaling its operations, including leading Silk Road’s initial public offering in 2019, and his role has continued to expand. Prior to Silk Road Medical, Mr. Buchanan’s background includes investing, business development, and operating roles at The Vertical Group, Impax Laboratories, Medtronic, and Ernst & Young. He holds an MBA in Health Care Management from The Wharton School at the University of Pennsylvania and a BA in Economics from Duke University.

Read More: https://endologix.com/news/endologix-announces-that-lucas-buchanan-joins-board-of-directors/

John Davis’ resume includes serving as a test engineer of radar systems on the Apollo modules that went to the moon. Click to listen.

Read More: ​https://www.reviewjournal.com/livewell/it-can-kill-you-retiree-urges-awareness-of-carotid-artery-disease-2890000/

A new study led by researchers from the University of Chicago Medicine (Chicago, USA) has revealed that nearly 75% of acute stroke patients wait more than two hours to be transferred to a comprehensive stroke center (CSC)—a treatment delay that creates an increased risk of long-term disability.

“In neurology, we often say that ‘time is brain’,” said Shyam Prabhakaran (University of Chicago, Chicago, USA), senior author on the study, which has been published in the Journal of the American Medical Association (JAMA). “For every 15 minutes that pass without treatment, prior research shows there is a steady decrease in the chances of good outcomes for stroke patients. Getting to the right hospital quickly can be lifesaving.”

Analysing recent data from over 100,000 patients at 1,925 hospitals across the USA, the researchers found that the median time between initial arrival and departure for transfer—known as door-in-door-out (DIDO) time—was 174 minutes, with almost three in four patients waiting longer than the recommended maximum of 120 minutes.

Read More: ​https://neuronewsinternational.com/us-registry-study-reveals-75-of-acute-stroke-patients-wait-more-than-two-hours-for-csc-transfer/

Sean Duffy has already raised hundreds of millions of dollars for his enterprise health company that is blending technology, behavior science, and medicine together. 

On the Dealmakers Show Duffy talked about providing virtual care, innovating in the rigid and highly regulated US healthcare system, making sales at the enterprise level, managing boards, and leadership.

Read More: https://alejandrocremades.com/this-entrepreneur-raised-over-450-million-to-deliver-virtual-chronic-care-solutions/

A less invasive procedure to reduce the risk of stroke by clearing blockages of the carotid artery in the neck is being offered more widely as a result of recent approval by the Food & Drug Administration.
The procedure, called transcarotid artery revascularization, or TCAR, employs the unusual technique of temporarily reversing the flow of blood away from the brain in order to reduce the risk of stroke during and after the surgery.
Previously, this relatively new endovascular approach was reserved by the FDA for only a small subset of patients. However, several years of data has shown it is as safe and successful as the more traditional endarterectomy “open surgery,” while also offering the benefits of a quicker recovery, smaller incision and reduced risk of nerve injury.

Read More: https://baptisthealth.net/baptist-health-news/going-against-the-flow-innovative-tcar-procedure-lowers-stroke-risk/

One of the most frustrating things for our patients who had a stroke is the inability to perform activities of daily living because of the weakness of the upper limb.

The current therapies we prescribe are quite limited. Many of these therapies have not been shown to induce the neuroplastic changes important for long-lasting recovery.

We are excited to offer our patients the Vivistim® System to magnify their potential to recover further.

Read More: ​https://www.linkedin.com/posts/microtransponder_rehabilitationawarenessweek-powerofmedicalrehab-activity-6978029271642456064-zlCA/?utm_source=share&utm_medium=member_desktop

We’re thrilled to announce that Hinge Health has been recognized in Employee Benefit News's 2022 Excellence in Benefits Awards! It's a reflection of Karen Stander, FACHE, Inessa Lurye, and the whole women’s pelvic health team's tireless work over the past year to help address the benefits gap that many women face when it comes to pelvic floor disorders. We’re proud to be a part of the conversation that advances the narrative around a condition that one in four women are silently suffering from: https://lnkd.in/dQHnYaFr

This week neurosurgeon Dr. Peter Warnke and his team [at UChicago Medicine] successfully completed the first vagus nerve stimulation implantation procedure in the Midwest. Paired with rehabilitation this implant can help patients who have suffered from a stroke regain hand and arm movements.

Read More: https://www.linkedin.com/posts/microtransponder_this-week-neurosurgeon-dr-peter-warnke-activity-6974009311421202432-cALU/?utm_source=share&utm_medium=member_desktop

The randomized controlled multicenter study is the first-of-its kind to investigate LITT benefits in radiographically recurrent brain metastasis patients
MINNETONKA, Minn. – Sept. 7, 2022 – Monteris Medical announced today that the first patient has been enrolled in its REMASTer (Recurrent Brain Metastases After Stereotactic Radiosurgery [SRS] Trial) clinical trial. This randomized controlled study is designed to investigate laser interstitial thermal therapy (LITT) using the NeuroBlate System as an early intervention for radiographically progressive brain metastases and to provide Level I evidence to guide treatment for this complex patient population.
Treatment of recurrent brain metastases is challenging as no standardized care currently exists within the clinical community for patients with disease progression following SRS. This is primarily attributed to the uncertainty of the underlying cause being either recurrence or radiation necrosis. In recent years, LITT has proved to be an effective tool for both causes of progression after SRS and can be performed during the same procedure as needle biopsy. Recent published studies suggest that LITT plus SRS may be superior to LITT alone or repeat SRS alone for treatment of biopsy-proven brain metastasis recurrence after SRS failure, even after controlling for variables known to predict progression. Recent literature also has revealed LITT to be effective for the treatment of radiation necrosis, with a superior time to steroid independence compared to medical management alone.
The REMASTer trial is designed to determine the superior treatment algorithm for both the recurrent tumor and radiation necrosis populations. The study will enroll 154 patients at up to 12 sites. Primary endpoints for the study include time to local intracranial progression or death and time to steroid cessation. Additional endpoints include comparison of treatment approaches with respect to overall survival, quality of life, and cognitive changes over time.

Read More: ​https://www.monteris.com/press-releases/monteris-medical-announces-first-patient-enrolled-in-remaster-clinical-study-on-neuroblate-system-for-metastatic-brain-tumor-patients/

Read More: ​https://finance.yahoo.com/news/silk-road-medical-announces-first-201500112.html